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11.1 The Tau-Aggregation Pathology of Alzheimer’s
Disease
Alzheimer’s disease (AD) is an irreversible, neurodegenerative disorder char-
acterised by the progressive loss of memory and thinking skills. It was ﬁrst
presented at a meeting in 1906 by Dr. Alois Alzheimer, a German psychiatrist,
who discovered ‘‘neuroﬁbrillary tangles’’ in the brain tissue of a woman who
died with dementia at the age of 55.1 It was not until the tangle could be iso-
lated and puriﬁed that its structure2–4 and composition could be determined.5,6
The neuroﬁbrillary tangles are composed predominantly of tau protein, a
protein essential for neuronal shape and axonal transport and the aggregation
of tau is closely linked both to clinical dementia and cell death.7–9 These
ﬁndings have also been aﬃrmed by others in the ﬁeld.10–14
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Neuroﬁbrillary tangles are intraneuronal clusters of aberrant tau protein
polymers that consist of ‘‘paired helical ﬁlaments’’ (PHFs), thus termed from
their characteristic double-twisted ribbon shape. The neuroﬁbrillary tangle and
its constituent PHFs are shown in Figure 11.1. PHFs have a fuzzy outer coat
accounting for about 20% of the mass of the ﬁlament that can be removed by
digestion with proteases leaving behind a stable inner core (Figures 11.1A–D)
which retains the characteristic twisted ribbon structure. A monoclonal anti-
body (mAb 423), raised against core-PHFs, labels both isolated core ﬁlaments
and intact PHFs (Figure 11.1E). Further research led to the discovery that the
molecular conﬁguration recognised by this monoclonal had been created in the
brain by a series of events depicted in Figure 11.1F.15 The short tau fragment of
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Figure 11.1 Neuroﬁbrillary pathology is composed of aggregated tau in ﬁlaments.
The ﬁlaments have a fuzzy coat (A) that can be removed by proteolysis
(B). Immunolabelling shows that the fuzzy coat contains N-terminal
parts of tau (C) that are removed by proteolysis (D), while the remaining
PHF core contains fragments truncated at Glu-391 and recognised by
mAb 423 (E). mAb 423 immunoreactivity can be demonstrated in PHFs
and in intracellular pretangle tau oligomers without prior treatment with
proteases and this is represented schematically (F). All neuroﬁbrillary
pathology is visualised in AD brain tissue using mAb 423 (NFT, neu-
roﬁbrillary tangle; NT, neuropil threads; NP, neuritic plaque) (G). The
process of aggregation has been simulated in an in vitro assay, using
antibodies speciﬁc to the N-terminus (499) and C-terminal truncation of
tau (423); dotted lines indicate sites of proteolytic cleavage (H).
211Rationale for Tau-Aggregation Inhibitor Therapy in Alzheimer’s Disease
which the core-PHF is principally composed creates the monoclonal antibody
recognition site by means of a high-aﬃnity binding and digestion process,
leading to a speciﬁc C-terminal truncation at position Glu-391 in the tau
molecule recognised by mAb 423. Thus, the entire spectrum of the tau-aggre-
gation pathology seen in a histological section of the AD brain (Figure 11.1G)
bears the hallmark of this aggregation/truncation process that can be modelled
in the test tube (Figures 11.1F and A). This process underlies the tau-aggre-
gation cascade described further in Section 11.2.
The image in Figure 11.1G serves to illustrate very clearly a simple fact that has
often been lost sight of within the dominant b-amyloid theory, namely the sheer
extent of the tau-aggregation pathology that is characteristic of AD. AD is the
most common in a family of neurodegenerative disease characterised by pro-
minent aggregation of tau protein, generally termed ‘‘tauopathies’’ (Figure 11.2).
The tauopathy of AD follows a highly characteristic pattern of spread of tau-
aggregation pathology, illustrated in Figure 11.3. The characteristic overall
distribution of neuroﬁbrillary tangle pathology in the human brain in AD is
shown in Figure 11.3A. It is most severe where it begins in the hippocampus
and entorhinal cortex (ERC). As the disease progresses, tangles spread to the
temporal, parietal and frontal cortices. This characteristic distribution of the
tau-aggregation pathology seen postmortem closely matches the pattern of
defects that can be demonstrated by functional brain scans during life. These
scans reveal patterns of reduced neuronal function, either by way of reduced
blood ﬂow (HMPAO-SPECT) or reduced glucose utilisation (FDG-PET). As
CN
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Figure 11.2 The tauopathies are neurodegenerative diseases characterised by tau-
aggregation pathology (A). Those denoted with an asterisk have cases
directly linked to mutations in the tau-protein gene. These mutations are
typically clustered around the same repeat domains (B) found in the core-
PHF structure (see Figures 11.1 and 11.7). Nearly 40 mutations have
been identiﬁed, including 7 intronic mutations (open asterisk) that aﬀect
alternative splicing of exon 10 within the repeat domains.
212 Chapter 11
shown in Figure 11.3B, there is progressive deterioration in neuronal function
in the regions of progressive accumulation of aggregated tau. These scan def-
icits match the clinical progression of AD as measured by the mini-mental state
examination (MMSE).16,17
This stereotyped pattern of spread of pathology has been formalised into the
Braak staging system,18 illustrated in Figure 11.3C. By taking a single brain
slice through the brain region shown by the vertical line in Figure 11.3A, the
spread of tau aggregation can be staged on the basis of microscopic exam-
ination of the brain into the six Braak stages illustrated in Figure 11.3C. It
should be noted that Braak attempted to devise a staging system based on the
b-amyloid pathology of AD, but showed that this was not possible because it
appears to be a general feature of the aging brain, and does not appear to
follow any clear pattern of progression or spread. It has since been conﬁrmed
by numerous studies that there is minimal if any systematic relationship
between b-amyloid pathology and cognitive decline.19–22
Braak staging therefore provides a useful unifying schema for bringing
together all of the key processes that characterise the evolution of AD from its
earliest detectable stages through to end-stage dementia. This is shown in
Figure 11.4. Figure 11.3B shows the approximate relationship between Braak
stages and the defects shown by HMPAO-SPECT scan.16 In Figure 11.4A, the
relationship between Braak stage and decline in MMSE score is shown.8 This
data comes from a prospective clinicopathological study conducted in an epi-
demiologically deﬁned cohort in the Cambridge area in which patients were
followed in the community by means of repeat assessment every 12–24 months.
Because cases were followed irrespective of disease severity or diagnosis, it
became possible to establish a calibration between level of cognitive function
and Braak stage, once cases with vascular pathology were excluded. What is
striking in Figure 11.3B is that already at preclinical and early clinical stages of
AD, brain pathology has already advanced to Braak stages 2 and 3. The
transition to Braak stage 4 corresponds to disease severity generally meeting
agreed clinical criteria for a diagnosis of AD.
The process of tau aggregation begins in the neocortical regions well before
neuroﬁbrillary tangles appear (Figure 11.4). Tau aggregation, in the form of
proteolytically stable PHFs, can be detected from Braak stage 2 onwards.
Tangles that can be visualised by conventional microscopy do not appear until
Braak stage 4 in the neocortex. As will be shown below, the time interval
between Braak stages 2 and 4 is about 20 years. There is therefore a long
pretangle/preclinical and early clinical period during which therapeutic inter-
vention in the tau-aggregation cascade can be achieved.
Tau aggregation begins in the form of submicroscopic formations referred to
as tau oligomers (Figure 11.5). This progress to ﬁlaments (i.e. PHFs) that, when
they occupy the whole of the intracellular space, are referred to as a neuroﬁ-
brillary tangle (‘‘NFT’’). This eventually chokes the neurone by eliminating the
possibility of normal neuronal metabolism and in the process eventually leaves
behind an extracellular ‘‘ghost’’ tangle as the only marker of a previously
existing neurone.
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The progressive accumulation of ghost tangles also follows Braak stages.
Tangle-mediated cell death begins in the entorhinal cortex at Braak stage 2 and
progresses thereafter. Destruction of neurones in the hippocampus begins at
around Braak stage 3 and likewise progresses at a lower rate. Finally, tangle-
mediated neuronal destruction does not become apparent in the neocortical
regions (frontal, temporal and parietal neocortex) until Braak stage 5.
These ﬁgures illustrate that the whole process of tau-aggregation pathology
follows an impressive and very clearly deﬁned sequence, from the earliest stages
when tau oligomers and ﬁlaments begin to form, through to the ﬁnal stages
when neurones are killed by the mature neuroﬁbrillary tangles. All of these
processes at the pathological level map to clinically measurable stages of cog-
nitive deﬁcit and physically to stages of loss of brain function that can be
measured by currently available brain-scanning techniques.
Braak staging can also be mapped throughout the human lifespan. In a
major study, Braak’s group reported the results of one of the largest human
postmortem studies ever conducted in 847 cases in whom age and Braak stage
were reported between ages 45–95.23 There were approximately 17 cases per
year of life throughout this age span. A Kaplan–Meier survival analysis using
this data is shown in Figure 11.6. The probability of transition from one stage
to a later stage demonstrates that there is a simple age-dependent transition to
higher Braak stages with advancing age (Figure 11.6A). This indicates that,
irrespective of the claims of the b-amyloid theory regarding speciﬁc genetic
causation of AD, the entire process is clearly embedded within the blueprint of
the general aging human population and regardless of speciﬁc genetic factors
that may accelerate the process in some individuals.
The survival plot can be transformed into a prevalence plot at speciﬁc Braak
stages. This gives a cross-sectional view of population progression by age
through the Braak stages through the ages 40–95. The peak for Braak stage 1 is
around 50 years. Considering the population aged 65 and over, only 24% will
remain at Braak stage 0 for the remainder of their lives. Of the 41% of the
population who progress to Braak stage 2, which peaks at around age 65, 92%
will progress to Braak stage 3, which peaks at around age 75. Progression to
Braak stage 4 is limited by the reduction in survival population beyond age 75.
The most surprising conclusion to be drawn from Figure 11.6B is that Braak
stage 2, which appears clinically innocuous from Figure 11.4 (i.e. corresponds
to the maximum MMSE score of 30), is actually already on what appears to be
a largely irreversible pathway of future inexorable disease progression. This
analysis is fundamentally at odds with the claims made by the b-amyloid school
Figure 11.3 Braak staging of Alzheimer’s disease. Tau aggregation spreads in a
characteristic neuroanatomical pattern (A) and the distribution of tau
pathology matches the pattern of SPECT scan defects seen in early stages
of AD (B). (C) The Braak staging of the spread of tangles from medial
temporal lobe to neocortex can be assessed in a single brain slice (C). [B
from Nishimura et al. 200716 and C from Braak and Braak, 1991;18 with
permissions].
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Figure 11.4 Braak staging measures cognitive decline (A), tau aggregation (B), neu-
roﬁbrillary tangle pathology (C) and tangle-mediated neuronal destruc-
tion (D). Results from a prospective clinicopathological study.7,8
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of thought, to the eﬀect that tau-aggregation pathology is a late-stage event and
therefore not amenable to therapeutic intervention. On the contrary, the real
challenge facing the ﬁeld is to identify those individuals at Braak stage 2 in
whom prevention of the further progression of pathology could essentially
eliminate AD from the aging human blueprint.
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Figure 11.6 The epidemiological implications of Braak staging with respect to age.
(A) Age-speciﬁc probability of Braak stage transitions calculated from
the data derived from 847 postmortems.3 (B) Estimated prevalence of
diﬀerent Braak stages by age for the US population.
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Figure 11.5 Development of tau pathology initiates with the deposition of Tau, ﬁrst as
oligomeric species that then progress to ﬁlaments. These PHFs accumu-
late and develop into the NFTs. Defective axonal transport aﬀects the
transport of APP to synapses and its recycling in the opposite direction,
thus leading to an accumulation of Ab in the form of the mature, neuritic
senile plaque. This, together with PHF-tau from other neurites, con-
stitutes the neuritic senile plaque. Finally, the extracellular ‘‘ghost’’ tangle
remains as a vestige of the neuron that has been destroyed.
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11.2 The Molecular Mechanics of Tau Aggregation in
Alzheimer’s Disease
As indicated above, PHFs which come from intracellular tangles are asso-
ciated with a fuzzy outer coat that can be removed by proteolysis, which
reveals the twisted ribbon structure of the core-PHF. What is more impor-
tant to understand is that removal of the fuzzy coat removes all of the
phosphorylated tau immunoreactivity that is present in PHFs, and that this
does not aﬀect the structural stability of the ﬁlament. The only tau-protein
fragment present within the core of the PHF is a short fragment of only
about 100 amino acid residues in length that comes from the repeat-domain of
tau. That is, it represents less than a quarter of the full-length tau
molecule. How this fragment comes into existence in the brain and why it
should be found as the fundamental building block of the core-PHF came
from studies that showed that the core-tau unit of the core-PHF has the
remarkable property that it is able to reproduce itself at the expense of
normal tau.8
The core fragment of tau attached to a solid-phase permits a high-aﬃnity
binding interaction with full-length tau (Figure 11.7A). This locks the repeat
domain of the bound full-length molecule into a proteolytically stable conﬁg-
uration that is essentially identical to the starting fragment. That is, the
digestion step with a broad spectrum exoprotease recreates the core-tau frag-
ment. Digestion removes the other parts of the molecule, but fails to remove the
bound segment that constitutes the new replicate of the original core-tau
template. The fundamental problem is that the proteolytically stable aggregate
retains the ability to bind yet more normal tau protein through subsequent
binding/digestion cycles. This process creates the mAb 423 antibody recogni-
tion site already alluded to in Figure 11.1, and shown to be such a prominent
feature of the AD tauopathy.
The process shown schematically in a cell-free environment (Figure 11.7A)
was also conﬁrmed in a cellular environment in the form of a stable cell line
suitable for screening of tau-aggregation inhibitors (Figure 11.7B).24 In this cell
line, expression of normal full-length tau is under the control of an inducer that
can be turned on in the presence of IPTG (arrow-head). The cell line also has
very low level constitutive expression of the core-tau PHF unit (thick arrow).
The levels of the latter have to be extremely low, otherwise toxic aggregates are
readily formed. When tau expression is turned on, by the addition of IPTG,
there is a conversion of the full-length tau into the truncated core-tau PHF unit.
This induction is associated with the appearance of tau protein aggregates that
are recognised by a proprietary, ﬂuorescent aggregation-dependent ligand
(Figures 11.7C and D). Simple overexpression of full-length tau does not lead
to aggregation in this model.
The capacity of tau-protein pathology to propagate itself at the expense of
normal tau was conﬁrmed in recent independent studies. Aggregated ﬁbrils of
tau243-375 can be taken up into cells in vitro containing full-length tau and
passed on to neighbouring cells to seed aggregation.25 Similarly, the
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transmission and spread of tau pathology from tau-mutant mice into normal
mice was achieved, provided the latter already expressed human full-length tau
protein.26
The place of tau-aggregation pathology and of Tau aggregation inhibitor
therapy is illustrated schematically in Figure 11.8. In general, the critical event
in triggering the tau-aggregation cascade is the nucleation or seeding event
(Figure 11.8A). Once the seeding event has occurred, the tau-aggregation
cascade is self-propagating, and leads to two deleterious outcomes. It converts
normal functional tau protein into the truncated aggregated form found in
PHFs. This leads to a loss of normal tau protein,27 needed to stabilise axonal
microtubules for linking diﬀerent parts of the brain. More importantly, as
alluded to above, the tau aggregates are directly neurotoxic and eventually lead
to neuronal death.
Although the b-amyloid school of thought sets great store by the abnor-
mal processing of APP and/or presenilin as a critical upstream trigger for the
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Figure 11.7 The core-PHF is composed of truncated tau protein that aggregates via
an autocatalytic process of binding and proteolysis, depicted schemati-
cally (A). In a cellular model (B), induction of expression of full-length
tau (arrowhead) leads to the accumulation of 12-kDa truncated tau
(arrow) in cells constitutively expressing low levels of truncated tau that
serves as a seed for tau capture and propagation. Cells are labelled by a
ﬂuorescent PHF-ligand only after induction (C) and not in the absence of
IPTG (D).
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tau-aggregation cascade, a more general age-related abnormality in the endo-
somal-lysosomal processing pathway may be much more important, particu-
larly the processing of mitochondria.28 There are now two examples
of tauopathies caused by genetically inherited abnormalities in the endo-
somal-lysosomal processing pathway: Niemann–Pick Type C29 and San-
ﬁlippo Syndrome Type B30 entirely unrelated to any abnormality in APP
processing.
In the case of sporadic AD, we consider that an age-related defect in the
turnover of mitochondria is more important than APP.28 This is illustrated
in Figure 11.8B. Mitochondria are the obligate energy source for neuronal
metabolism and their turnover period is approximately 6 months. Long-lived,
nondividing cells such as neurones show signs of failure in the turnover of
mitochondria-derived proteins as they age. These take the form of so-called
aging pigments, or lipofuscin, which are in fact composed predominantly
of unprocessed products of mitochondrial turnover.31 These same proteins
are found in close association with early-stage tau aggregates in the AD
brain, and biochemical analyses show they have the ability to form resistant
proteolytically stable complexes with tau. We have observed colocalisation of
the mitochondrially derived proteins (porin, core protein 2 of complex III and
ATP synthase subunit 9) with early tau aggregates. An example is shown for
porin and tau (Figure 11.8C). Essentially identical images have been produced
in Sanﬁlippo syndrome showing colocalisation of tau with lysozyme and a
lysosomal form of ATP-synthase subunit C.30
The system whose failure is responsible for clearance of mitochondria-
derived proteins is the endosomal-lysosomal processing pathway, and is exactly
the same pathway required for processing mutant membrane-bound proteins,
such as APP and the presenilin proteins.32 Therefore, mutations in these pro-
teins may add to the congestion and dysfunction in this pathway without
actually being directly causative of AD.
Once tau aggregation has been initiated, the only pathway available for
clearance of the tau oligomers is the same congested endosomal-lysosomal
pathway. The capacity of the neuron to clear proteolytically stable tau oligo-
mers is therefore critically compromised, leading to uncontrolled progression
of the tau-aggregation process. The progressive rate of accumulation
of aggregated tau in the form of PHFs is, in fact, exponential over time
(Figure 11.9). This can be calculated on the basis of levels of aggregated tau
protein measured in neocortex at diﬀerent Braak stages (as shown for exam-
ple in Figure 11.4B) and real time between Braak stages, calculated for example
from the data shown in Figure 11.6A.23 From this it is possible to deduce
the level of aggregated tau in neocortex as a function of time in years
(Figure 11.9).
The critical transition points such as conversion to Braak stages 2–4 and the
appearance of clinically visible dementia occur about 7 years after the
transition to the steep exponential phase of tau aggregation in neocortex
(Figure 11.9, arrow). This occurs about 25 years after the transition to Braak
stage 1.
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11.3 The Basis of Tau-Aggregation Inhibitor Therapy
Given the autocatalytic/self-propagating nature of the tau-aggregation cascade,
it is possible to construct a mathematical model of a system that contains a self-
propagating component (Figure 11.10A). In this model, normal tau protein is
diverted into an aggregation cascade with a positive feedback component.
There are two diﬀerent timeframes operating in the data incorporated into the
model. The times required for aggregation and clearance phenomena in vitro
are relatively short (hours/days) whereas the time scale over which aggregates
build up in the brain is measured in years, i.e. the time scale of Braak staging.
Since production and clearance can be shown in vitro and in cell models to
reach equilibrium over a short time (hours/days), the progressive slow build-up
of aggregated tau over years cannot be explained by short-acting internal
equilibrium processes. Rather, the progressive accumulation over time must be
due to progressive failure of clearance that undergoes very gradual degrada-
tion. This is envisaged as a slow deterioration in the capacity of the endosomal-
lysosomal system to deal with clearance of oligomers and larger tau aggregates.
We have modelled this by incorporating the time required for the aggregation
and dissolution processes observed in vitro, and an underlying long-term
component that leads to decreased clearance capacity over time.
It then becomes possible to calculate the predicted consequences of inter-
vention on the input side or enhancement on the clearance side (Figure 11.10A).
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Figure 11.9 The exponential accumulation of aggregated tau in neocortex in humans
calculated from a prospective clinicopathological study based on Braak
staging. The arrow indicates stage at which clinically visible dementia is
observed.
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Although it seems intuitively obvious that inhibition on the input side should be
beneﬁcial, the model output indicates that the beneﬁt of input-side intervention
would be short lived (Figure 11.10B). The two axes represent time (in years) and
corresponding PHF levels (e.g. in neocortex based on data such as that shown in
Figure 11.9). The surprising conclusion is that a treatment that reduces the
inﬂux of tau into the aggregating cascade would be expected to have clinical
characteristics of a purely symptomatic treatment. Despite input-side inter-
vention appearing to act mechanistically on what might be postulated to be a
rate-limiting aspect of the disease process, the net eﬀect would be to produce
only a transient reduction in levels of aggregated tau, but would have no eﬀect
on the long-term rate of accumulation of aggregated tau in the brain over time
(Figure 11.10B). In other words, the intervention would be expected to produce
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Figure 11.10 Opening up a new clearance pathway via tau disaggregation of oligo-
mers via a tau-aggregation inhibitor (TAI) is the only way to aﬀect the
rate of disease progression. The tau-aggregation cascade proceeds by an
autocatalytic process of binding and proteolysis of tau. (A) Braak
progression is likely driven by age-related impairment in clearance of
aggregated tau (i.e. progressive degradation of the endosomal-lysoso-
mal pathway (see Figure 11.8B). (B) Only by enhancing clearance of
oligomers by means of TAI treatment is the rate of progression of AD
likely to be altered. (C) Inhibiting the inﬂow to the cycle will not aﬀect
the levels of aggregated tau accumulating at each Braak stage. Thus,
upstream inhibition of factors that initiate tau capture are unlikely to
alter the rate of progression of AD.
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only transient beneﬁt, and not impact on the subsequent rate of disease pro-
gression. On the other hand, an intervention on the output side of the process
(i.e. enhanced clearance) would have the eﬀect of altering the disease progres-
sion trajectory.
This appears somewhat counterintuitive but, but it is possible to explain in
simpler terms what the mathematical model is showing (Figure 11.10C). One
might envisage this as a system in which there is ﬂow of water into and out of a
dam. At equilibrium, input equals output, but input does not determine the level
of water in the dam. The water level can be taken as analogous to the Braak
stage, or level of aggregated tau in the brain. This is determined by the height of
the barrier. Because inhibition on the input side could not conceivably achieve
100% eﬃcacy, the eﬀect of retarding input will produce a short-lived reduction
that will again reach an equilibrium determined by the height of the barrier at a
lower input/output equilibrium. The only way to avoid this, therefore, is to
devise a treatment that lowers the level of the barrier.
The dynamics of this model apply irrespective of the biological mechanism
that is postulated as being critical on the upstream side. This might be envi-
saged as tau hyperphosphorylation (despite the strictly biological arguments
against the phosphorylation hypothesis of tau aggregation28) or some other
putative upstream mechanism that might be mediated by APP. In short, the
model predicts that upstream intervention in a process that has an autocatalytic
component is essentially useless. Furthermore, it has been shown recently that
tau-protein expression is actually required for Ab-induced neuronal dysfunc-
tion and cognitive impairment in transgenic mice.33
11.4 Methylthioninium Chloride as a Tau-Aggregation
Inhibitor
Methylthioninium chloride (MTC; Structure 11.1) was the ﬁrst tau-aggregation
inhibitor (TAI) reported15 and the only TAI yet to be tested in clinical trials for
AD.
S
N
NN
Cl
TAI therapy, such as that provided by MTC, acts essentially on the output side
by enhancing clearance. The fundamental kinetic block in the clearance of
aggregated tau is envisaged as being due to the state of aggregation itself. MTC
was shown to reverse the proteolytic stability of the tau-protein fragment of the
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core-PHF by disaggregating the polymer, permitting the release of the core-tau
monomer.15 In its monomeric state, the core-tau unit of the PHF is extremely
sensitive to proteases. PHFs disaggregate in the presence of MTC and MTC is
eﬀective at submicromolar concentrations in cell-free and cellular assays used
to screen TAI activity (Figure 11.11).
The activity of MTC has been tested in vivo in two proprietary transgenic
mouse models. In the ﬁrst model, ‘‘Line 1’’ mice express the core-tau unit of the
PHF linked with a short N-terminal signal-sequence and under the control of a
neuron-speciﬁc Thy-1 promoter (Figure 11.12A).34 The purpose of the signal
sequence is to force tau aggregation by targetting expression to a system cap-
able or providing an initiation binding substrate, i.e. the endoplasmic reticu-
lum, and simultaneously forcing tau clearance into the endosomal-lysosomal
pathway reproducing the conditions for a failure of this clearance pathway in
Cell-free tau-tau 
binding assay
Cellular tau 
aggregation assay
Native PHF 
disaggregation assay
IC50 (μM) for MTC 195.6 ± 16.1 (10) 0.59 ± 0.036 (73) 0.14 ± 0.01 (2) 
Schematic 
representation of 
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Key: Tau
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Figure 11.11 MTC is a tau-aggregation inhibitor that dissolves both oligomers and
ﬁlaments. (A) Inhibitory activity of MTC in three assays shown dia-
grammatically. (B) Oligomeric tau produced in cells, as indicated by a
12-kDa fragment, is removed by MTC. (C) PHFs isolated from AD
brain tissue are dissolved by increasing concentrations of MTC (a,
0.01%; b, 0.1% and c–e, 1%).
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Figure 11.12 Line 1 mouse expresses truncated tau targeted to membrane via a signal
sequence peptide (SS:296-390Tau; A). Pathology develops ﬁrst in hip-
pocampus and entorhinal cortex before progressing to other cortical
areas (B, C). Pathology (D) and behavioural deﬁcits in water maze
learning (E) respond to treatment with MTC. (tg, transgenic; wt, wild
type; e, entorhinal cortex; h, hippocampus; r, retrosplenial cortex; v,
visual cortex; a, auditory cortex; s, subiculum; am, amygdala).
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respect of tau. The net eﬀect is to produce a pathology that reaches the stage
of oligomers but not of fully formed ﬁlaments or neuroﬁbrillary tangles
(Figure 11.12B). The mice reproduce the essential phenomena of Braak staging
(Figure 11.12C). In mice less than 12 months of age, the aggregated-tau
pathology is located predominantly in the entorhinal cortex and hippocampus,
but little in other brain regions. As mice age, the pathology spreads into iso-
cortical brain regions (retrosplenial, visual and auditory cortices and sub-
iculum). There is a reduction in the counts of tau-positive neurones containing
oligomeric tau after mice have been treated with MTC (administered either
orally or intravenously) (Figure 11.12D).
Line 1 mice develop a learning impairment after about 7 months of age, as
shown for example in a modiﬁed Morris water maze,35 in which the task is to
ﬁnd a hidden platform with a minimum number of trials. Line 1 mice require
about twice as many trials to reach a given learning criterion and oral treatment
with MTC reverses this learning defect (Figure 11.12E).
Truncated tau was directed to the endoplasmic reticulum in Line 1 mice to
enable the initiation of tau nucleation and avoid the toxic eﬀects observed by
overexpressing truncated tau within cells. Mice expressing mutant tau exhibit
increased tau associated with rough ER in motor neurons and a greater number
of contacts between rough ER and mitochondria was observed.36 Increased tau
was also associated with a rough ER fraction extracted from AD brains
compared with controls.
MTC also exhibits eﬃcacy in a second proprietary mouse model (‘‘Line 66’’;
Figure 11.13). In this case, a full-length tau construct with two mutations, at
P301S (associated with frontotemporal dementia with Parkinsonism linked
with chromosome 17, FTDP-1737), and a further mutation at G335D shown to
further enhance tau aggregation in vitro. Whereas the Line 1 mouse exhibits
diﬀuse neuronal tau pathology, the Line 66 mouse, has severe tau pathology, to
an extent similar to that noted by other researchers expressing tau with FTDP-
17 mutations in transgenic mice.38–40 Tau tangles that stain positively with
Bielschowsky silver and with thioﬂavin S indicate their ﬁlamentous nature. Tau
pathology is observed in CA1 and CA3 of the hippocampus, entorhinal and
other cortical areas (Figure 11.13B).
Line 66 mice show a severe abnormality of motor learning whereby they are
unable to learn how to remain on a rotating rod (Figure 11.13C). Following
oral treatment with MTC (1mg/kg), however, this learning deﬁcit is reversed.
Somewhat higher doses (10mg/kg) are required to reverse tau pathology in
hippocampus and entorhinal cortex (Figure 11.13D). It is possible to extract
protease-resistant 12-kDa tau from brains of Line 66 mice, indicating the
presence of AD-like ﬁlaments of tau. This protease-resistant tau can be dis-
solved in the presence of MTC (Figure 11.13E).
Thus, MTC is able to reverse both the behavioural and pathological eﬀects
that arise in vivo in two transgenic mouse models of tau aggregation: a cognitive
phenotype model in which tau oligomers predominate (Line 1) and a fronto-
temporal-like motor phenotype in which abundant ﬁlamentous tau accumu-
lates (Line 66).
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Figure 11.13 Transgenic ‘‘FTDP-type’’ tau mice (A) exhibit tau pathology
throughout brain including hippocampus (B) and a motor phenotype.
Both the pathology in entorhinal cortex and hippocampus (C) and
motor learning on a Rotarod (D) are improved following oral treatment
of Line 66 mice with MTC. Protease-resistant 12-kDa tau from brains is
also sensitive to MTC (E, arrow).
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11.5 Clinical Application of Tau-Aggregation Inhibitor
Therapies
MTC was the ﬁrst tau-aggregation inhibitor described,15 and several other
polymerisation inhibitors have since been reported. These include benzothia-
zole derivatives,41,42 Congo red derivatives and anthraquinones,43 2,3-di(furan-
2-yl)-quinoxalines,44 phenylthiazolyl-hydrazide,45 polyphenols and porphyr-
ins,46 cyanin dyes47 and aminothienopyridazines.48
Importantly, MTC selectively avoids disruption of the normal tau–tubulin
interaction.15 MTC has been used clinically since Paul Ehrlich ﬁrst reported its
use as an analgesic and in the treatment of malaria over a century ago.49 Its
main therapeutic use has been in the intravenous treatment of methaemoglo-
binaemia50 and as an oral urinary antiseptic. It has also had clinical use in CNS,
where it has been used to treat ifosfamide encephalopathy51 and manic
depression and psychosis.52 MTC is not only a tau-aggregation inhibitor in
vitro, but a compound that crosses the blood/brain barrier and demonstrates
eﬃcacy in reducing tau pathology and in relieving cognitive and motor learning
symptoms in tau transgenic mice.
Furthermore, the rationale for using the TAI therapeutic approach has been
conﬁrmed by the results from a phase 2 clinical trial in 321 patients diagnosed
with mild or moderate AD.53 MTC reduced the rate of disease progression by
84% over 50 weeks when measured by the ADAS-cog scale and a 100%
reduction on the MMSE scale, the two most common means to evaluate the
usefulness of AD therapeutics. This result is a marked increase over the 30–
50% reduction deﬁned as desirable for an AD disease modifying agent by a
European Task Force Consensus Statement.54 These results were further sup-
ported by brain scans that allowed the visualisation of MTC-related prevention
of loss of neuronal function as shown by a HMPAO-SPECT scan in a 55%
subpopulation of the primary clinical study.55 The accumulated data suggests
that MTC has the potential not only to slow the rate of AD progression, but
may even halt it and restore neuronal function, particularly at early stages of
the disease.
References
1. A. Alzheimer, Allg. Z. Psych. Psych.-gerich. Med., 1907, 64, 146–148.
2. R. A. Crowther and C. M. Wischik, EMBO J., 1985, 4, 3661–3665.
3. C. M. Wischik, R. A. Crowther, M. Stewart and M. Roth, J. Cell Biol.,
1985, 100, 1905–1912.
4. C. M. Wischik and R. A. Crowther, Br. Med. Bull., 1986, 42, 51–56.
5. C. M. Wischik, M. Novak, H. C. Thøgersen, P. C. Edwards, M. J.
Runswick, R. Jakes, J. E. Walker, C. Milstein, R. M. and A. Klug, Proc.
Natl. Acad. Sci. USA, 1988, 85, 4506–4510.
6. C. M. Wischik, M. Novak, P. C. Edwards, A. Klug, W. Tichelaar and
R. A. Crowther, Proc. Natl. Acad. Sci. USA, 1988, 85, 4884–4888.
229Rationale for Tau-Aggregation Inhibitor Therapy in Alzheimer’s Disease
7. F. Garcı´a-Sierra, C. M. Wischik, C. R. Harrington, J. Luna-Mun˜oz and
R. Mena, J. Chem. Neuroanat., 2001, 22, 65–77.
8. E. B. Mukaetova-Ladinska, F. Garcia-Sierra, J. Hurt, H. J. Gertz, J. H.
Xuereb, R. Hills, C. Brayne, F. A. Huppert, E. S. Paykel, M. McGee,
R. Jakes, W. G. Honer, C. R. Harrington and C. M. Wischik, Am. J.
Pathol., 2000, 157, 623–636.
9. C. R. Harrington, E. B. Mukaetova-Ladinska, R. Hills, P. C. Edwards,
E. Montejo de Garcini, M. Novak and C. M. Wischik, Proc. Natl. Acad.
Sci. USA, 1991, 88, 5842–5846.
10. N. Zilka, P. Filipcik, P. Koson, L. Fialova, R. Skrabana, M. Zilkova,
G. Rolkova, E. Kontsekova and M. Novak, FEBS Lett., 2006, 580,
3582–3588.
11. M. von Bergen, S. Barghorn, L. Li, A. Marx, J. Biernat, E. M. Mandelkow
and E. Mandelkow, J. Biol. Chem., 2001, 276, 48165–48174.
12. T. C. Gamblin, M. E. King, H. Dawson, M. P. Vitek, J. Kuret, R. W. Berry
and L. I. Binder, Biochemistry, 2000, 39, 6136–6144.
13. E. Grober, D. Dickson, M. J. Sliwinski, H. Buschke, M. Katz, H. Crystal
and R. B. Lipton, Neurobiol. Aging, 1999, 20, 573–579.
14. D. R. Thal, T. Arendt, G. Waldmann, M. Holzer, D. Zedlick, U. Ru¨b and
R. Schober, Neurobiol. Aging, 1998, 19, 517–525.
15. C. M. Wischik, P. C. Edwards, R. Y. K. Lai, M. Roth and C. R. Har-
rington, Proc. Natl. Acad. Sci. USA, 1996, 93, 11213–11218.
16. T. Nishimura, K. Hashikawa, H. Fukuyama, T. Kubota, S. Kitamura,
H. Matsuda, H. Hanyu, H. Nabatame, N. Oku, H. Tanabe, Y. Kuwabara,
S. Jinnouchi and A. Kubo, Ann. Nuc. Med., 2007, 21, 15–23.
17. M. F. Folstein, S. E. Folstein and P. R. McHugh, J. Psychiatr. Res., 1975,
12, 189–198.
18. H. Braak and E. Braak, Acta Neuropathol., 1991, 82, 239–259.
19. G. K. Wilcock and M. M. Esiri, J. Neurol. Sci., 1982, 56, 407–417.
20. C. R. Harrington, J. Louwagie, R. Rossau, E. Vanmechelen, R. H. Perry,
E. K. Perry, J. H. Xuereb, M. Roth and C. M. Wischik, Am. J. Pathol.,
1994, 145, 1472–1484.
21. H. Crystal, D. Dickson, P. Fuld, D. Masur, R. Scott, M. Mehler,
J. Masdew, C. Kwas, M. Aronson and L. Wolfson, Neurology, 1988, 38,
1682–1687.
22. P. W. Arriagada, J. H. Growdon, E. T. Hedley-White and B. T. Hyman,
Neurology, 1992, 42, 631–639.
23. T. G. Ohm, H. Mu¨ller, H. Braak and J. Bohl, Neuroscience, 1995, 64, 209–
217.
24. C. M. Wischik, D. Horsley, J. E. Rickard and C. R. Harrington, PCT
International Application, 2002, WO02/055720.
25. B. Frost, R. L. Jacks and M. I. Diamond, J. Biol. Chem., 2009, 284,
12845–12852.
26. F. Clavaguera, T. Bolmont, R. A. Crowther, D. Abramowski, S. Frank,
A. Probst, G. Fraser, A. K. Stalder, M. Beibel, M. Staufenbiel, M. Jucker,
M. Goedert and M. Tolnay, Nature Cell Biol., 2009, 11, 909–914.
230 Chapter 11
27. R. Y. K. Lai, H.-J. Gertz, D. J. Wischik, J. H. Xuereb, E. B. Mukaetova-
Ladinska, C. R. Harrington, P. C. Edwards, R. Mena, E. S. Paykel,
C. Brayne, F. A. Huppert, M. Roth and C. M. Wischik, Neurobiol. Aging,
1995, 16, 433–445.
28. C. M. Wischik, R. Y. K. Lai and C. R. Harrington, in Microtubule-
Associated Proteins: Modiﬁcations in Disease., ed. J. Avila, R. Brandt and
K. S. Kosik, Harwood Academic Publishers, Amsterdam, Editon edn.,
AQ1 1997, pp. 185–241.
29. S. Love, L. R. Bridges and C. P. Case, Brain, 1995, 118, 119–129.
30. K. Ohmi, L. C. Kudo, S. Ryazantsev, H.-Z. Zhao, S. L. Karsten and
E. F. Neufeld, Proceedings of the National Academy of Sciences, 2009, 106,
8332–8337.
31. D. N. Palmer, R. D. Martinus, S. M. Cooper, G. G. Midwinter, J. C. Reid
and R. D. Jolly, J. Biol. Chem., 1989, 264, 5736–5740.
32. R. A. Nixon and A. M. Cataldo, Trends Neurosci., 1995, 18, 489–496.
33. E. D. Roberson, K. Scearce-Levie, J. J. Palop, F. Yan, I. H. Cheng, T. Wu,
H. Gerstein, G.-Q. Yu and L. Mucke, Science, 2007, 316, 750–754.
34. C. M.Wischik, J. E. Rickard, D. Horsley, C. R. Harrington, F. Theuring, K.
Stamer and C. Zabke, PCT International Application, 2002, WO02/059150.
35. G. Chen, K. S. Chen, J. Knox, J. Inglis, A. Bernard, S. J. Martin,
A. Justice, L. McConlogue, D. Games, S. B. Freedman and R. G. M.
Morris, Nature, 2000, 408, 975–979.
36. S. Perreault, O. Bousquet, M. Lauzon, J. Paiement and N. Leclerc,
J. Neuropathol. Exptl. Neurol., 2009, 68, 503–514.
37. O. Bugiani, J. R. Murrell, G. Giaccone, M. Hasegawa, G. Ghigo,
M. Tabaton, M. Morbin, A. Primavera, F. Carella, C. Solaro, M. Grisoli,
M. Savoiardo, M. G. Spillantini, F. Tagliavini, M. Goedert and B. Ghetti,
J. Neuropathol. Exptl. Neurol., 1999, 58, 667–677.
38. B. Allen, E. Ingram, M. Takao, M. J. Smith, R. Jakes, K. Virdee,
H. Yoshida, M. Holzer, M. Craxton, P. C. Emson, C. Atzori, A. Migheli,
R. A. Crowther, B. Ghetti, M. G. Spillantini and M. Goedert, J. Neurosci.,
2002, 22, 9340–9351.
39. J. Go¨tz, F. Chen, R. Barmettler and R. M. Nitsch, J. Biol. Chem., 2001,
276, 529–534.
40. J. Lewis, E. McGowan, J. Rockwood, H. Melrose, P. Nacharaju, M. Van
Slegtenhorst, K. Gwinn-Hardy, M. P. Murphy, M. Baker, X. Yu, K. Duﬀ,
J. Hardy, A. Corral, W.-L. Lin, S.-H. Yen, D. Dickson, P. Davies and M.
Hutton, Nature Genet., 2000, 25, 402–405.
41. N. S. Honson, J. R. Jensen, A. Abraha, G. F. Hall and J. Kuret, Neurotox.
Res., 2009, 15, 274–283.
42. G. F. Hall, S. Lee and J. Yao, J. Mol. Neurosci., 2002, 19, 253–260.
43. M. Pickhardt, Z. Gazova, M. von Bergen, I. Khlistunova, Y. Wang,
A. Hascher, E.-M. Mandelkow, J. Biernat and E. Mandelkow, J. Biol.
Chem., 2005, 280, 3628–3635.
44. A. Crowe, C. Ballatore, E. Hyde, J. Q. Trojanowski and V. M. Y. Lee,
Biochem. Biophys. Res. Commun., 2007, 358, 1–6.
231Rationale for Tau-Aggregation Inhibitor Therapy in Alzheimer’s Disease
45. M. Pickhardt, G. Larbig, I. Khlistunova, A. Coksezen, B. Meyer, E. M.
Mandelkow, B. Schmidt and E. Mandelkow, Biochemistry, 2007, 46,
10016–10023.
46. S. Taniguchi, N. Suzuki, M. Masuda, S.-i. Hisanaga, T. Iwatsubo, M.
Goedert and M. Hasegawa, J. Biol. Chem., 2005, 280, 7614–7623.
47. C. Chirita, M. Necula and J. Kuret, Biochemistry, 2004, 43, 2879–2887.
48. A. Crowe, W. Huang, C. Ballatore, R. L. Johnson, A.-M. L. Hogan,
R. Huang, J. Wichtermann, J. McCoy, D. M. Huryn, D. S. Auld, I. I. I. A.
B. Smith, J. Inglese, J. Q. Trojanowski, C. P. Austin, K. R. Brunden and
V. M. Y. Lee, Biochemistry, 2009, [Advance publication: http://dx.doi.org/
10.1021/bi9006435].
49. J. E. Kristiansen, Dan. Med. Bull., 1989, 36, 178–185.
50. A. Mansouri and A. A. Lurie, Am. J. Hematol., 1993, 42, 7–12.
51. A. Kupfer, C. Aeschlimann, B. Wermuth and T. Cerny, Lancet, 1994, 343,
763–764.
52. G. J. Naylor, B. Martin, S. E. Hopwood and Y. Watson, Biol. Psychiatry,
1986, 21, 915–920.
53. C. M.Wischik, P. Bentham, D. J. Wischik and K. M. Seng, Alzheimer’s and
Dementia, 2008, 4, T167.
54. B. Vellas, S. Andrieu, C. Sampaio, N. Coley and G. Wilcock, Lancet
Neurol., 2008, 7, 436–450.
55. R. T. Staﬀ, T. S. Ahearn, A. D. Murray, P. Bentham, K. M. Seng and C.
Wischik, Alzheimer’s and Dementia, 2008, 4, T775.
232 Chapter 11
